Patient Bladder Cancer Urothelial Carcinoma staging treatment

BCG Bladder Bladder Neoplams Cancer Cystectomie Cystectomy Cytologie Urinaire Cytology Medical Subject Headings (MeSH) Carcinome Urothélial Medical Subject Headings (MeSH) Urothelial Carcinoma Survie Survival Tumeurs De La Vessie Vessie.

Bladder Invasive Urothelial Carcinoma PD-L1 (SP263) Immunohistochemical Detection Consensus

Adjuvant Chemotherapy Bladder-sparing Chemoradiation Enhanced Recovery after Surgery Muscle-invasive Bladder Cancer Neoadjuvant Chemotherapy Radical Cystectomy Transurethral Resection of Bladder Tumor Trimodal Urothelial Carcinoma of Bladder Variant Histology

CT Urography Diagnostic Samples Diagnostics UTUC Upper Tract Urothelial Carcinoma Ureteroscopy

Urothelial Carcinoma Bladder Cytology Bladder Neoplams Cancer BCG Cystectomy Survival

AUC Appropriate Use Criteria Appropriateness Criteria Bladder Cancer CT MRI Muscle-invasive Bladder Cancer Staging Urothelial Carcinoma

Humans Female *Urinary Bladder Neoplasms/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Prognosis Proportional Hazards Models Meta-analysis Muscle-invasive bladder urothelial carcinoma Non-muscle-invasive bladder urothelial carcinoma Sex

Humans Immune Checkpoint Inhibitors/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/drug therapy Proportional Hazards Models Eastern Cooperative Oncology Group Immune checkpoint inhibitor Performance status Urothelial carcinoma

Humans *Urinary Bladder Neoplasms *Carcinoma Transitional Cell/surgery/pathology Ureteroscopy/adverse effects/methods *Ureteral Neoplasms/surgery/pathology *Kidney Neoplasms/surgery/pathology Antegrade Endoscopic surgery Kidney-sparing surgery Retrograde Upper tract urothelial carcinoma

Humans *Carcinoma Transitional Cell/pathology *Urinary Bladder Neoplasms/genetics DNA Methylation Neoplasm Recurrence Local/genetics Prognosis *Urologic Neoplasms/genetics/pathology Membrane Proteins/genetics Neoplasm Proteins/genetics Biomarkers Kaplan-Meier survival Meta-analysis Methylation Upper tract urothelial carcinoma

Humans *Urinary Bladder/pathology Cystectomy/methods Prognosis Prospective Studies Neoplasm Recurrence Local/pathology *Urinary Bladder Neoplasms/pathology Biomarkers biomarker neutrophil-to-lymphocyte ratio prognostic factor radical cystectomy recurrence urothelial carcinoma

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Administration Intravesical Combined Modality Therapy Cystectomy/*methods Humans Neoplasm Recurrence Local/*epidemiology Network Meta-Analysis Randomized Controlled Trials as Topic Urethra Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/epidemiology/*surgery #BladderCancer #blcsm #uroonc blue-light cystoscopy hexaminolevulinic acid narrow band imaging non-muscle-invasive urothelial carcinoma photodynamic diagnosis single immediate intravesical chemotherapy

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma

Area Under Curve *Carcinoma Transitional Cell Humans In Situ Hybridization Fluorescence ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/pathology Biomarker Cytology Diagnostic Fluorescent in situ hybridization (FISH) Meta-analysis Upper urinary tract urothelial carcinoma (UTUC)

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Humans *Carcinoma Renal Cell/surgery Prognosis Nutritional Status *Carcinoma Transitional Cell/surgery *Urinary Bladder Neoplasms Nephrectomy *Kidney Neoplasms/surgery Retrospective Studies Controlling Nutritional Status score Renal cell carcinoma Upper tract urothelial carcinoma

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.